Ellen Vitetta

Q: What Schools Are Affiliated With Ellen Vitetta

Ellen Vitetta is affiliated with the following schools: Washington University in St. Louis, Kyushu University, Wayne State University, Stanford University, University of Washington, Connecticut College, New York University, University of Texas Southwestern Medical Center

Ellen Vitetta's AcademicInfluence.com Rankings

Ellen Vitetta

Biology

#2142

World Rank

#3438

Historical Rank

Immunology

#132

World Rank

#139

Historical Rank

biology Degrees

Download Badge

Biology

Ellen Vitetta's Degrees

PhD Immunology University of Texas Southwestern Medical Center

Why Is Ellen Vitetta Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Ellen S. Vitetta is the director of the Cancer Immunobiology Center at the University of Texas Southwestern Medical Center in Dallas. Background Vitetta earned a Bachelor of Arts degree at Connecticut College and advanced degrees at New York University Medical and Graduate Schools.

(See a Problem?)

Ellen Vitetta's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells (1988) (942)
HER-2 gene amplification can be acquired as breast cancer progresses. (2004) (560)
T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells (1982) (414)
Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. (1984) (396)
Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1 (1985) (395)
Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells (1988) (393)
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. (1995) (350)
CELL SURFACE IMMUNOGLOBULIN II. ISOLATION AND CHARACTERIZATION OF IMMUNOGLOBULIN FROM MOUSE SPLENIC LYMPHOCYTES (1971) (349)
Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes (2008) (346)
Redesigning nature's poisons to create anti-tumor reagents. (1987) (338)
Phase I immunotoxin trial in patients with B-cell lymphoma. (1991) (313)
Immunotoxins: a new approach to cancer therapy. (1983) (273)
Immunoglobulin-receptors revisited. (1975) (271)
Vascular leak syndrome: a side effect of immunotherapy. (1997) (254)
Functional and ontogenetic analysis of murine CD45Rhi and CD45Rlo CD4+ T cells. (1990) (247)
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. (2006) (244)
Immunotoxins: magic bullets or misguided missiles? (1993) (224)
Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study (2002) (223)
Cancer dormancy: Opportunities for new therapeutic approaches (1997) (206)
Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. (2001) (197)
Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. (1999) (191)
Memory B and T cells. (1991) (184)
Cell surface immunoglobulin. XI. The appearance of an IgD-like molecule on murine lymphoid cells during ontogeny (1975) (181)
Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. (2002) (176)
Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. (2002) (168)
Synthesis of germ-line gamma 1 immunoglobulin heavy-chain transcripts in resting B cells: induction by interleukin 4 and inhibition by interferon gamma. (1989) (167)
Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. (1980) (166)
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. (2003) (166)
Biochemical evidence linking the GIX thymocyte surface antigen to the gp69/71 envelope glycoprotein of murine leukemia virus (1975) (152)
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. (1996) (151)
Molecular similarities between the Qa-2 alloantigen and other gene products of the 17th chromosome of the mouse (1977) (145)
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. (2002) (141)
B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines (1986) (141)
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. (1997) (138)
Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice (2003) (138)
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. (2005) (137)
Cellular interactions in the humoral immune response. (1989) (135)
Differential susceptibility of neonatal and adult murine spleen cells to in vitro induction of B-cell tolerance (1976) (129)
CELL SURFACE IMMUNOGLOBULIN (1972) (126)
Pancreatic Ductal Adenocarcinoma (2012) (126)
In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins (1982) (124)
Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. (1997) (120)
HIV-infected cells are killed by rCD4-ricin A chain. (1988) (120)
Characterization of the physical interaction between antigen-specific B and T cells. (1986) (119)
The protein products of the murine 17th chromosome: genetics and structure. (1978) (118)
Disseminated or localized growth of a human B‐cell tumor (Daudi) in scid mice (1990) (116)
Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor β loci sequences (2003) (114)
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. (2000) (114)
IgD and B Cell Differentiation (1977) (114)
Selective killing of leukaemia cells by antibody–toxin conjugates: implications for autologous bone marrow transplantation (1982) (113)
T Cell‐Derived Lymphokines That Induce IgM and IgG Secretion in Activated Murine B Cells (1984) (113)
TLR-independent neutrophil-derived IFN-γ is important for host resistance to intracellular pathogens (2013) (112)
Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. (1991) (112)
Cell surface immunoglobulin. V. Release from murine splenic lymphocytes. (1972) (111)
B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. (1985) (110)
Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. (1993) (109)
The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. (1992) (108)
Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF (2016) (107)
Association of a beta2-microglobulin-like subunit with H-2 and TL alloantigens on murine thymocytes. (1975) (107)
Interleukin 4 mediates autocrine growth of helper T cells after antigenic stimulation. (1986) (107)
A novel recombinant vaccine which protects mice against ricin intoxication. (2002) (104)
An allosteric model for heterogeneous receptor complexes : Understanding bacterial chemotaxis responses to multiple stimuli (2006) (103)
Structural similarities between a product of the T/t-locus isolated from sperm and teratoma cells, and H-2 antigens isolated from splenocytes. (1975) (103)
Engineering therapeutic monoclonal antibodies (2008) (103)
Organization of the immune response genes. (1979) (102)
BCL1, a Murine Model for Chronic Lymphocytic Leukemia: Use of the Surface Immunoglobulin Idiotype for the Detection and Treatment of Tumor (1979) (101)
Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. (1994) (100)
RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. (2007) (97)
A pilot clinical trial of a recombinant ricin vaccine in normal humans (2006) (96)
Isolation of heavy and light chains of immunoglobulin from the surfaces of lymphoid cells. (1971) (96)
A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies (2004) (96)
The differential expression of homing and adhesion molecules on virgin and memory T cells in the mouse. (1991) (96)
Purification of ricin A1, A2, and B chains and characterization of their toxicity. (1986) (95)
Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins (1991) (95)
Memory T cells are anergic to the superantigen staphylococcal enterotoxin B (1992) (95)
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. (2003) (95)
IFN-γ enhances secretion of IgG2a from IgG2a-committed LPS-stimulated murine B cells: Implications for the role of IFN-γ in class switching (1991) (93)
Immunotherapy of multiple myeloma (1995) (91)
Evaluation of ricin A-chain immunotoxins directed against human T cells. (1986) (88)
Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. (1983) (88)
Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. (1988) (87)
A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia (2009) (87)
Clonal analysis of B cells induced to secrete IgG by T cell-derived lymphokine(s) (1984) (85)
Highly purified CD25- resting T cells cannot be infected de novo with HIV-1. (1997) (85)
Cell surface immunoglobulin. VII. Synthesis, shedding, and secretion of immunoglobulin by lymphoid cells of germ-free mice. (1974) (84)
Evaluation of four CD22 antibodies as ricin a chain‐containing immunotoxins for the in vivo therapy of human B‐cell leukemias and lymphomas (1988) (83)
Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. (1993) (80)
Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. (2005) (79)
A phase I study of a combination of anti‐CD19 and anti‐CD22 immunotoxins (Combotox) in adult patients with refractory B‐lineage acute lymphoblastic leukaemia (2011) (78)
B-cell tolerance. III. Effect of papain-mediated cleavage of cell surface IgD on tolerance susceptibility of murine B cells (1977) (78)
The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. (2000) (77)
Structural studies on the murine Ia alloantigens. V. Evidence that the structural gene for the I-E/C beta polypeptide is encoded within the I- A subregion (1979) (77)
A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. (1990) (77)
Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells. (1983) (77)
Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin (2000) (77)
Neoplastic B Cells as Targets for Antibody‐Ricin A Chain Immunotoxins (1982) (77)
Lymphokine-induced IgM secretion by clones of neoplastic B cells (1983) (76)
Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. (1994) (76)
Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. (2007) (74)
Immunotoxins containing ricin or its A chain. (1991) (74)
Role of CD25+ and CD25-T cells in acute HIV infection in vitro. (1993) (73)
Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. (2005) (73)
Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells. (1994) (73)
Absence of H-2 antigens capable of reacting with cytotoxic T cells on a teratoma line expressing a T/t locus antigen. (1975) (72)
Cancer dormancy: studies of the murine BCL1 lymphoma. (1991) (72)
Beta 2-microglobulin is selectively associated with H-2 and TL alloantigens on murine lymphoid cells (1976) (71)
Induction of B cell differentiation by T cell factors. I. Stimulation of IgM secretion by products of a T cell hybridoma and a T cell line. (1981) (71)
T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. (1996) (71)
Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin Administration (2008) (71)
Immunotoxins: redirecting nature's poisons (1985) (69)
Characterization of a spontaneous murine B cell leukemia (BCL1). I. Cell surface expression of IgM, IgD, Ia, and FcR. (1979) (68)
Detection of tumor cells in the peripheral blood of nonleukemic patients with B-cell lymphoma: analysis of "clonal excess". (1980) (68)
Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. (1986) (68)
Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization. (1988) (67)
Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. (2002) (67)
In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. (1988) (66)
Regulation of the expression of multiple class II genes in murine B cells by B cell stimulatory factor-1 (BSF-1). (1986) (66)
Cancer dormancy: isolation and characterization of dormant lymphoma cells. (1993) (66)
The importance of cellular internalization of antibody-targeted carbon nanotubes in the photothermal ablation of breast cancer cells (2011) (66)
Effects of specific anti‐B and/or anti‐plasma cell immunotherapy on antibody production in baboons: depletion of CD20‐ and CD22‐positive B cells does not result in significantly decreased production of  anti‐αGal antibody (2001) (65)
Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. (2004) (65)
Isolation and characterization of a molecular complex containing thy‐1 antigen from the surface of murine thymocytes and t cells (1973) (65)
Relationship between trinitrophenyl and H-2 antigens on trinitrophenyl-modified spleen cells. I. H-2 antigens on cells treated with trinitrobenzene sulfonic acid are derivatized. (1977) (63)
Immunotoxins in the therapy of cancer: from bench to clinic. (1994) (62)
Specific thermal ablation of tumor cells using single‐walled carbon nanotubes targeted by covalently‐coupled monoclonal antibodies (2009) (61)
Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice (1995) (59)
Surface Ig isotypes on cells responding to lipopolysaccharide by IgM and IgG secretion. (1979) (58)
The partial amino-acid sequence of an H-2K molecule. (1976) (58)
Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain (1984) (58)
Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. (1995) (58)
Interaction and Activation of Antigen‐Specific T and B Cells (1987) (58)
Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. (1998) (57)
Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection (2015) (57)
Phase I Trial of an Anti‐CD19 Deglycosylated Ricin A Chain Immunotoxin in Non‐Hodgkin's Lymphoma: Effect of an Intensive Schedule of Administration (1995) (56)
In vitro activation of murine antigen-specific memory B cells by a T-dependent antigen. (1986) (55)
Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. (1997) (55)
Synergy between immunotoxins prepared with native ricin A chains and chemically-modified ricin B chains. (1986) (54)
T cell-derived B cell growth and differentiation factors. Dichotomy between the responsiveness of B cells from adult and neonatal mice (1983) (54)
Adhesion molecules as targets for cancer therapy. (1997) (54)
Immunotoxins and vascular leak syndrome. (2000) (53)
Activation of antigen-specific B cells: role of T cells, cytokines, and antigen in induction of growth and differentiation. (1983) (53)
Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 Immunotoxin (1997) (53)
Isolation and characterization of H-2 and TL alloantigens from the surface of mouse lymphocytes. (1972) (53)
Structural studies on the murine IA alloantigens. II. Molecular weight characterization of the products of the I-A and I-E/C subregions. (1978) (53)
Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. (1995) (53)
Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. (1989) (52)
An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. (2004) (52)
The relationship between surface immunoglobulin isotype and immune function of murine B lymphocytes II. Surface immunoglobulin isotopes on unprimed B cells in the spleen (1977) (52)
Double isotype production by a neoplastic B cell line. II. Allelically excluded production of mu and gamma 1 heavy chains without CH gene rearrangement (1986) (51)
Pilot Phase IB Clinical Trial of an Alhydrogel-Adsorbed Recombinant Ricin Vaccine (2012) (51)
Interactions between receptors for interleukin 2 and interleukin 4 on lines of helper T cells (HT-2) and B lymphoma cells (BCL1) (1989) (50)
Epitopes on CD45R [T200] molecules define differentiation antigens on murine B and T lymphocytes. (1988) (50)
Blocking of primary in vitro antibody responses to thymus-independent and thymus-dependent antigens with antiserum specific for IgM or IgD. (1978) (50)
Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation. (1983) (50)
The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. (1991) (49)
Interleukin 4 induces changes in the chromatin structure of the gamma 1 switch region in resting B cells before switch recombination (1990) (49)
The effect of anti-immunoglobulin antibodies on the in vitro proliferation and differentiation of normal and neoplastic murineB cells. (1980) (49)
The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. (2001) (48)
The Role of Receptor IgM and IgD in Determining Triggering and Induction of Tolerance in Murine B Cells 1 (1979) (48)
Cytotoxicity of a recombinant ricin‐A‐chain fusion protein containing a proteolytically‐cleavable spacer sequence (1990) (47)
Murine B cell leukemia (BCL1): organ distribution and kinetics of growth as determined by fluorescence analysis with an anti-idiotypic antibody. (1979) (47)
Activation of antigen-enriched b cells. I. Purification and response to thymus-independent antigens. (1983) (47)
Characterization of a B cell defect in the NZB mouse manifested by an increased ratio of surface IgM to IgD. (1978) (46)
IL-4 induces the specific rearrangement of gamma 1 genes on the expressed and unexpressed chromosomes of lipopolysaccharide-activated normal murine B cells. (1989) (46)
Cell surface immunoglobulin. XVIII. Functional differences of B lymphocytes bearing different surface immunoglobulin isotypes (1976) (46)
Limiting dilution analysis of CD45Rhi and CD45Rlo T cells: further evidence that CD45Rlo cells are memory cells. (1990) (46)
Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. (1988) (46)
Structural studies on the murine Ia alloantigens--III. Tryptic peptide comparisons of allelic products of the I-E/C sub-region. (1979) (45)
Activation of antigen-enriched B cells. II. Role of linked recognition in B cell proliferation to thymus-dependent antigens. (1983) (44)
Induction of murine B cell proliferation by insolubilized anti-immunoglobulins. (1980) (42)
Recent developments in immunotoxin therapy. (1994) (42)
IFN-gamma enhances secretion of IgG2a from IgG2a-committed LPS-stimulated murine B cells: implications for the role of IFN-gamma in class switching. (1991) (42)
CELL SURFACE IMMUNOGLOBULIN (1971) (41)
An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. (1988) (41)
Homology of (murine) H–2 and (human) HLA with a chicken histocompatibility antigen (1977) (41)
Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. (1995) (41)
Characterization of the spontaneous murine B cell leukemia (BCL1). III. Evidence for monoclonality by using an anti-idiotype antibody. (1979) (40)
Adult T cell leukemia: a potential target for ricin A chain immunotoxins. (1985) (40)
Synthesis, Transport, Dynamics and Fate of Cell Surface Ig and Alloantigens in Murine Lymphocytes (1973) (40)
Release of cell surface immunoglobulin by mouse splenic lymphocytes. (1972) (40)
Qa-2, H-2K, and H-2D alloantigens evolved from a common ancestral gene (1981) (40)
Induction of proliferation and differentiation of neoplastic B cells by anti-immunoglobulin and T-cell factors. (1981) (39)
A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas (2001) (39)
The relationship between surface immunoglobulin isotype and immune function of murine B lymphocytes. IV. Role of IgD-bearing cells in the propagation of immunologic memory. (1979) (39)
T and B lymphocytes: recognition and function (1979) (39)
Role of glycosylation in the H‐2‐restricted cytolysis of virus‐infected cells (1981) (39)
Mucoricin is a Ricin-Like Toxin that is Critical for the Pathogenesis of Mucormycosis (2020) (39)
A monoclonal anti-mouse LFA-1 alpha antibody mimics the biological effects of B cell stimulatory factor-1 (BSF-1). (1986) (39)
kappa/lambda Shifts do not occur during maturation of murine B cells. (1981) (38)
Immunoglobulin synthesis and secretion by cells in the mouse thymus that do not bear theta antigen. (1973) (38)
Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. (1993) (38)
Antigen-induced changes in the proportion of antigen-binding cells expressing IgM, IgG, and IgD receptors. (1979) (38)
Immunoglobulins and alloantigens on the surface of lymphoid cells. (1975) (38)
The potential use of immunotoxins in transplantation, cancer therapy, and immunoregulation. (1984) (38)
Passive and Active Vaccination Strategies to Prevent Ricin Poisoning (2011) (38)
Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. (1999) (37)
Expression of murine leukemia virus envelope glycoprotein gp69/71 on mouse thymocytes. Evidence for two structural variants distinguished by presence vs. absence of GIX antigen (1975) (36)
Relationship between trinitrophenyl and H-2 antigens on trinitrophenyl-modified spleen cells. II. Correlation between derivatization of H-2 antigens with trinitrophenyl and the ability of trinitrophenyl-modified cells to react functionally to the CML assay. (1977) (36)
Guinea pig immune response-related histocompatibility antigens. Partial characterization and distribution (1975) (36)
The toxicity of chemically deglycosylated ricin A-chain in mice. (1992) (35)
Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. (2010) (35)
A partial characterization of suppressor cells in the spleens of mice conditioned with fractionated total lymphoid irradiation (TLI). (1983) (35)
CELL SURFACE IMMUNOGLOBULIN IX. A NEW METHOD FOR THE STUDY OF SYNTHESIS, INTRACELLULAR TRANSPORT, AND EXTERIORIZATION IN MURINE SPLENOCYTES (1974) (35)
Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins. (1986) (34)
Cell surface immunoglobulin. XIII. Distribution of IgM and IgD-like molecules on small and large cells of mouse spleen. (1975) (34)
The Activation of Murine B Cells: The Role of Surface Immunoglobulins (1980) (34)
Antigen-induced changes in phospholipid metabolism in antigen-binding B lymphocytes. (1987) (34)
The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins. (1986) (34)
Ricin vaccine development. (2012) (33)
An immunologic approach for the detection of tumor cells in the peripheral blood of patients with malignant lymphoma; implications for the diagnosis of minimal disease. (1979) (33)
The murine B cell response to TNP-polyacrylamide beads: the relationship between the epitope density of the antigen and the requirements for T cell help and surface IgD. (1980) (33)
Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells. (1990) (32)
Metabolism of H‐2 and Thy‐1 (Θ) alloantigens in murine thymocytes (1974) (31)
Structural studies on the murine Ia alloantigens. IV. NH2-terminal sequence analysis of allelic products of the I-A and I-E/C subregions. (1979) (31)
A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity. (2010) (31)
Structural studies on protein products of murine chromosome 17: partial amino acid sequence of an H-2Kb molecule. (1976) (31)
Interleukin 4 enhances the ability of antigen-specific B cells to form conjugates with T cells. (1987) (30)
Considering Therapeutic Antibodies (2006) (30)
An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. (1999) (30)
Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain. (1988) (30)
Small and large B cells respond differently to T cell-derived B cell growth and differentiation factors. (1985) (30)
B cell growth and differentiation factors. (1985) (30)
Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. (2005) (29)
Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin. (1986) (29)
An in vivo model to study immunotoxin-induced vascular leak in human tissue. (1999) (29)
Preparation and analysis of antigen-specific memory B cells. (1985) (29)
Anti-receptor antibody. I. Isolation and characterization of the immunoglobulin receptor for phosphorylcholine. (1975) (29)
Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. (1993) (29)
Structure of RiVax: a recombinant ricin vaccine (2011) (29)
The antitumor activity of an anti‐CD54 antibody in SCID mice xenografted with human breast, prostate, non‐small cell lung, and pancreatic tumor cell lines (2008) (29)
Intracellular routing rather than cross-linking or rate of internalization determines the potency of immunotoxins directed against different epitopes of sIgD on murine B cells. (1991) (29)
Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers. (1990) (28)
Cell surface immunoglobulin. XV. The presence of IgM and an IgD‐like molecule on the same cell in murine lymphoid tissue (1976) (28)
Cell surface immunoglobulin. XIX. Susceptibility of IgD and IgM on murine splenocytes to cleavage by papain. (1976) (28)
The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice (2000) (27)
Isolation of antigen-binding virgin and memory B cells. (1986) (27)
The use of haptenated immunoglobulins to induce B cell tolerance in vitro. The roles of hapten density and the Fc portion of the immunoglobulin carrier. (1983) (27)
Induction of B cell tumor dormancy by anti-idiotypic antibodies. (1993) (26)
Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma (1996) (26)
Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity (2012) (25)
A B cell growth factor-like activity is secreted by cloned, neoplastic B cells. (1984) (25)
Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help. (2005) (25)
Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins. (1996) (25)
SYNTHESIS, INTRACELLULAR DISTRIBUTION, AND SECRETION OF IMMUNOGLOBULIN AND H-2 ANTIGEN IN MURINE SPLENOCYTES (1973) (25)
Effect of T cell-derived lymphokines containing B cell differentiation factor(s) for IgG (BCDFγ) on γ-specific mRNA in murine B cells (1983) (25)
Cell surface immunoglobulin. XXII. Reappearance of surface IgM and IgD on murine splenocytes after removal by capping. (1977) (24)
The relationship between surface immunoglobulin isotype and immune function of murine B lymphocytes. I. Surface immunoglobulin isotypes on primed B cells in the spleen (1977) (24)
21 – Production of Lymphokines by Murine T Cells Grown in Limiting Dilution and Long-Term Cultures (1982) (24)
Structural studies on the murine Ia alloantigens. VI. Evidence that both subunits of the I-A alloantigen are encoded by the I-A subregion. (1979) (24)
Immunotoxins for the Treatment of B-Cell Lymphomas (1997) (24)
Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells. (1996) (23)
Labeling characteristics and separation of Ia antigen subunits. (1978) (23)
The influence of immunization of female mice with F9 teratocarcinoma cells on their reproductive performance. (1979) (23)
Rituximab but not Other anti-CD20 Antibodies Reverses Multidrug Resistance in 2 B lymphoma Cell Lines, Blocks the Activity of P-glycoprotein (P-gp), and Induces P-gp to Translocate out of Lipid Rafts (2006) (23)
Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. (1994) (23)
Targeting mammalian target of rapamycin to both downregulate and disable the P-glycoprotein pump in multidrug-resistant B-cell lymphoma cell lines (2009) (22)
Cloning and expression of recombinant, functional ricin B chain. (1987) (22)
The Evaluation of Recombinant, Chimeric, Tetravalent Antihuman CD22 Antibodies (2004) (22)
B cell-associated LFA-1 and T cell-associated ICAM-1 transiently cluster in the area of contact between interacting cells. (1991) (22)
Synthesis, biochemistry and dynamics of cell surface immunoglobulin on lymphocytes. (1973) (22)
Chemical construction of immunotoxins (2001) (22)
Virgin T cells do not provide help for antigen-specific B cells in the absence of IL-4, IL-5, and IL-6. (1991) (22)
Donor T lymphocyte infusion following ex vivo depletion of donor anti-host reactivity by a specific anti-interleukin-2 receptor P55 chain immunotoxin. (2002) (21)
The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice. (2000) (21)
Covalent Binding of Human α2-Macroglobulin to Deglycosylated Ricin A Chain and Its Immunotoxins (1991) (21)
Immunoglobulin receptors on murine B lymphocytes. (1977) (21)
Pharmacokinetics of Antibodies and Immunotoxins in Mice and Humans (2004) (21)
Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate. (2007) (21)
Synthesis of surface H-2 alloantigens in murine splenocytes. (1975) (20)
Double isotype production by a neoplastic B cell line. I. Cellular and biochemical characterization of a variant of BCL1 that expresses and secretes both IgM and IgG1 (1986) (20)
The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. (1998) (20)
Rescue of rhesus macaques from the lethality of aerosolized ricin toxin. (2019) (20)
H-40, an antigen controlled by an Igh linked gene and recognized by cytotoxic T lymphocytes. I. Genetic analysis of H-40 and distribution of its product on B cell tumors (1984) (20)
Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. (2004) (19)
An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory. (2004) (19)
Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains. (1993) (19)
Studies on the murine Ss protein. I. Purification, molecular weight, and subunit structure (1975) (19)
The specific B cell subset lacking in the CBA/N mouse is not required for the production of autoantibody in (CBA/N x NZB)F1 male mice. (1980) (18)
Cell surface immunoglobulin. XIV. Synthesis, surface expression, and secretion of immunoglobulin by Peyer's patch cells in the mouse. (1975) (18)
Primary structural studies of the Qa-2 alloantigen: implications for the evolution of the MHC (1982) (18)
Relationship between trinitrophenol and H-2 antigens on trinitrophenyl-modified spleen cells. III. Quantitative aspects of trinitrophenol binding on cells treated with trinitrobenzene sulfonic acid. (1978) (18)
Chemical construction of immunotoxins. (2000) (18)
From the basic science of B cells to biological missiles at the bedside. (1994) (17)
IL-4-induced expression of germline gamma 1 transcripts in B cells following cognate interactions with T helper cells. (1992) (17)
Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing. (1994) (17)
Recombinant IL 2 but not recombinant interferon-gamma stimulates both proliferation and IgM secretion in a Ly-1+ clone of neoplastic murine B cells (BCL1). (1986) (17)
Activation of the γ1 gene by lipopolysaccharide and T cell-derived lymphokines containing a B cell differentiation factor for IgG1 (BCDFγ) (1985) (17)
Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function. (1990) (17)
Immunosuppression in a murine B cell leukemia (BCL1): role of an adherent cell in the suppression of primary in vitro antibody responses. (1981) (17)
The effects of cytokines and adherent cells on the interleukin 4-mediated induction of Ia antigens on resting B cells. (1987) (16)
The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life. (2005) (16)
Expression and functional properties of genetically engineered ricin B chain lacking galactose-binding activity. (1990) (16)
Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins (2016) (16)
A single antigen-specific B cell can conjugate to either a type 1 or a type 2 helper T cell. (1988) (16)
Characterization of murine leukemia virus-specific proteins. (1975) (16)
Interleukin-2 does not induce murine B cells to secrete Ig. (1982) (16)
A ricin A chain-containing immunotoxin that kills human T lymphocytes in vitro (1985) (16)
Treatment of premalignancy: prevention of lymphoma in radiation leukemia virus-inoculated mice by cyclosporin A and immunotoxin. (1992) (16)
Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160 (2016) (16)
Relationship between beta2-microglobulin and cell-surface alloantigens of the mouse. (1976) (15)
Structural studies on protein products of murine chromosome 17. III. Partial amino acid sequence of an H-2Kq molecule. (1978) (15)
Antigen-specific memory and virgin B cells differ in their requirements for conjugation to T cells. (1987) (15)
Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin. (2003) (15)
Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin. (1988) (15)
An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons. (2002) (15)
A peptide difference between the mu-chains from cell-associated and secreted IgM of the BCL1 tumor. (1980) (15)
Cell surface immunoglobulin. XII. Localization of immunoglobulin on murine lymphocytes by scanning immunoelectronmicroscopy (1975) (15)
Changes in expression of J11d on murine B cells during activation and generation of memory. (1991) (15)
The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25- quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus. (1996) (15)
Structural Studies on the Murine Ia Alloantigens (1978) (14)
Structural studies of H-2 and TL alloantigens. (1977) (14)
A reevaluation of CD22 expression in human lung cancer. (2014) (14)
Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia (2006) (14)
Immunotoxins containing ricin A or B chains with modified carbohydrate residues act synergistically in killing neoplastic B cells in vitro. (1985) (14)
Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines. (1993) (14)
Structural studies on the murine Ia alloantigens. VII. Further evidence for two-gene control of the E/C alloantigens. (1980) (13)
The Fc Portion of UV3, an Anti-CD54 Monoclonal Antibody, Is Critical for its Antitumor Activity in SCID Mice With Human Multiple Myeloma or Lymphoma Cell Lines (2006) (13)
Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics. (2006) (13)
Activation of murine B cells from different tissues with different mitogens. II. Isotype distribution of secreted immunoglobulins in the presence and absence of IL-4-containing T cell supernatants. (1987) (13)
CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients. (1991) (13)
The lineage relationship between virgin and memory B cells. (1992) (13)
Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain. (1990) (12)
Immunology. Considering therapeutic antibodies. (2006) (12)
DOUBLE ISOTYPE PRODUCTION BY A NEOPLASTIC (1986) (12)
Preparation and application of antibodies coupled to the A chain of ricin. (1983) (12)
In vivo reconstitution of ricin-like activity from its A and B chain subunits. (1984) (12)
The Generation and Anti-Myeloma Activity of a Chimeric Anti-CD54 Antibody, cUV3 (2004) (12)
A simplified microassay for inhibition of protein synthesis in reticulocyte lysates by immunotoxins. (1986) (12)
Partial Depletion of Regulatory T Cells Does Not Influence the Inflammation Caused by High Dose Hemi-Body Irradiation (2013) (12)
Specific killing of a human breast carcinoma cell line by a monoclonal antibody coupled to the A-chain of ricin (1981) (11)
B cell tolerance. I. Analysis of hapten-specific unresponsiveness induced in vitro in adult and neonatal murine spleen cell populations. (1977) (11)
Recent advances in the development of vaccines against ricin (2016) (11)
Partial characterization of Ia antigens from murine lymphoid cells (1974) (11)
A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells. (1993) (11)
Two independent pathways of helper activity provided by a single T cell clone. (1986) (11)
BCL1, a murine model of prolymphocytic leukemia. II. Morphology and ultrastructure. (1981) (11)
Cross-linking of interleukin 4 to surface molecules on murine T and B lymphocytes. (1989) (11)
The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains. (1995) (11)
T cell-derived b cell differentiation factor(s) effect on the isotype switch of murine b cells (2013) (11)
Structural analysis of thymus-leukemia (TL) antigens in the mouse. (1982) (11)
Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a 90Y-Labeled Anti-CD22 Monoclonal Antibody (2005) (10)
The use of haptenated-immunoglobulin molecules to induce tolerance in B cells from neonatal mice. (1985) (10)
Cell cycle-related expression of the receptor for a B cell differentiation factor. (1985) (10)
Staphylococcal enterotoxin B induces the expression of activation markers on murine memory T cells in the absence of proliferation or lymphokine secretion. (1995) (10)
Inhibition of the helper function of murine T cells with Fab'-anti-L3T4 ricin A chain immunotoxin. (1987) (10)
The response of B cells in spleen, Peyer's patches, and lymph nodes to LPS and IL-4. (1991) (10)
BCL1, a murine model of prolymphocytic leukemia. I. Effect of splenectomy on growth kinetics and organ distribution. (1981) (10)
Analysis of thymus-leukemia (TL) antigens with monoclonal antibodies. (1980) (10)
Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin (2020) (9)
Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein. (2008) (9)
Acquisition of cell surface IgD after in vitro culture of neoplastic B cells from the murine tumor BCL1 (1980) (9)
Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity. (1986) (9)
A ricin A chain-containing immunotoxin that kills human T lymphocytes in vitro. (1985) (9)
Zidovudine, Lamivudine, and Abacavir Have Different Effects on Resting Cells Infected with Human Immunodeficiency Virus In Vitro (2004) (9)
Tumor Dormancy and Cell Signaling. II. Antibody as an Agonist in Inducing Doi~iiiancy of a B Cell Lymphoma in SCID Mice By E. Racila,* R. H. Scheuermann,~ L. J. Picker,~ E. Yefenof,$ (1995) (9)
Antigen-specific sIalo B cells do not secrete IgG2a in response to TH1 cells and antigen: responsiveness can be restored by IL-4. (1990) (8)
Surface expression and synthesis of I-A and I-E/C encoded molecules by B lymphocytes and Ig-secreting cells. (1979) (8)
Induction of IL‐4 secretion by the radiation leukemia virus (RadLV): Role in autocrine growth stimulation of RadLV infected pre‐leukemic cells (1992) (8)
Cytotoxic T cells specific for antigens expressed on surface immunoglobulin-positive cells (1981) (7)
sIgD- and sIgD+ B cells responding to thymus-independent antigens have a different lymphokine requirement. (1985) (7)
T CELL-DERIVED B CELL DIFFERENTIATION FACTORS: (BCDF) : DEFINITION OF BCDFμ AND BCDFγ (1982) (7)
MEMORY BAND T CELLS (1991) (7)
Allelic exclusion of IgD allotypes on murine B cells. (1980) (7)
Relationship between trinitrophenol and H-2 antigens on trinitrophenyl-modified spleen cells. IV. Correlation between the loss of cell surface trinitrophenyl-H-2 molecules and functional activity of derivatized cells in an anti-TNP-CML assay. (1978) (7)
Role of surface immunoglobulin in B lymphocyte activation. (1984) (7)
Properties of the Lyb-2 molecule (1977) (7)
Studies on the protein products of murine chromosome 17:a status report. (1978) (7)
Immunotoxins: New therapeutic reagents for autoimmunity, cancer, and AIDS (1990) (6)
Activation of murine B cells with Salmonella typhimurium mitogen (STM), lipopolysaccharide (LPS), and dextran sulfate (DxS). I. Cell-cycle analysis and induction of cytoplasmic immunoglobulin. (1987) (6)
CELL SURFACE IMMUNOGLOBULIN (1972) (6)
Effect of sublethal irradiation of SCID mice on growth of B-cell lymphoma xenografts and on efficacy of chemotherapy and/or immunotoxin therapy. (1996) (6)
An anti-CD 19 antibody inhibits the interaction between P-glycoprotein ( Pgp ) and CD 19 , causes Pgp to translocate out of lipid rafts , and chemosensitizes a multidrug-resistant ( MDR ) lymphoma cell line (2004) (6)
Changes in phospholipid metabolism during B lymphocyte activation. (1986) (6)
CELL SURFACE IMMUNOGLOBULIN (1972) (6)
The effect of T cell-derived lymphokines on the levels of isotype-specific RNA in normal B cells. (1985) (5)
The isotype cycle: successive changes in surface immunoglobulin classes expressed by the antigen-binding B-cell population during the primary in vivo response. (1981) (5)
The processing of antigen and anti-Ig by antigen-specific B cells. (1989) (5)
Reconstitution of FOXP 3 regulatory T cells ( Tregs ) after CD 25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease (2007) (5)
The I region of the murine major histocompatibility complex: genetics and structure. (1980) (5)
Immunotoxins: magic bullets or misguided missiles? (1993) (5)
Immunological Relationships Among the Lower Trypanosomatidae (1967) (5)
The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy (2016) (5)
Endpoint and epitope-specific antibody responses as correlates of vaccine-mediated protection of mice against ricin toxin. (2020) (5)
T cell-derived B cell growth (BCGF) and differentiation (BCDF) factors: suppression of the activity of BCDF mu but not BCGF by murine bone marrow cells. (1983) (5)
Inactivation of antigen-responsive clones with antisera specific for IgM or IgD. (1978) (5)
Role of antibody signaling in inducing tumor dormancy. (1996) (5)
Analysis and detection of B cell neoplasms. (1980) (5)
6 – Collaboration between T and B cells (1990) (4)
Differentiation of bone marrow-derived lymphocytes. (1978) (4)
Induction of Proliferation and Differentiation of Murine B Cells Bearing Surface Igλ by Rat Monoclonal Antibody to λ Chain (1983) (4)
Vascular leak syndrome: A troublesome side effect of immunotherapy (multiple letters) (1998) (4)
Increased susceptibility to lethal effects of bacterial lipopolysaccharide in mice with B-cell leukemia. (1981) (4)
Failure of Vaccination With Idiotypic Protein or DNA, (+/−IL-2), the Depletion of Regulatory T Cells, or the Blockade of CTLA-4 to Prolong Dormancy in Mice With BCL1 Lymphoma (2005) (4)
Primary structural analysis of the Tla region gene products, QA-2 and TL. (1982) (4)
Monoclonal antibodies as carriers of toxins. (1989) (4)
A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines (2011) (3)
Anti-CD 19 Antibodies Inhibit the Function of the Pgp Pump in Multidrug-resistant B Lymphoma Cells 1 (1999) (3)
Evidence for a second class II (Ia) antigenic system in rats linked to RT1. (1979) (3)
Section Review Biologicals & Immunologicals The use of immunoconjugates in cancer therapy (1996) (3)
Cancer: Editorial overview (1999) (3)
Quantitative monitoring of lymphoid malignancies. Application and findings in chronic lymphocytic leukemia. (1983) (3)
IMMUNOGLOBULIN RECEPTORS REEVALUATED * (1982) (3)
Kinetics of the immune response of rabbits to lower trypanosomatidae antigens. (1968) (3)
Detection of unique peptides derived from the mu chains of cell surface but not secreted IgM. (1981) (3)
Induction of proliferation and differentiation of murine B cells bearing surface Ig lambda by rat monoclonal antibody to lambda chain. (1983) (3)
Erratum: A pilot clinical trial of a recombinant ricin vaccine in normal humans (Proceedings of The National Academy of Sciences of the United States of America (February 14, 2006) 103, 7 (2268-2273) 10.1073/pnas.0510893103) (2006) (3)
Role of Lymphokines in the Immune System (1990) (3)
Properties of 19s and 7s immuno globulins against crithidia fasciculata culex atcc 12857 abstract (1968) (3)
930 A clinical phase I study of an anti-CD25-deglycosylated ricin A-chain immunotoxin (RFT5-SMPT-DGA) in patients with refractory Hodgkin's disease (1995) (3)
The Emergence of Specific T Cell Clones During the Generationof GVHD (2001) (3)
Immunochemical purification and analysis of Qa and TL antigens. (1984) (3)
Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin (2020) (3)
The development of immunotoxins for the therapy of cancer, AIDS, and immune dysfunctions. (1988) (2)
Purification and characterization of antigen-binding virgin and memory B cells. (1987) (2)
Regulation of cell surface immunoglobulin and alloantigens on lymphocytes. (1974) (2)
THE USE OF ANTIBODY-RICIN A CHAIN IMMUNOTOXINS FOR THE THERAPY OF A B CELL LEUKEMIA (BCL 1 ) IN MICE (1982) (2)
The partial amino acid sequence of a murine Ia molecule (1977) (2)
Radioimmunotherapy of CD 22-Expressing Daudi Tumors in Nude Micewith a 90 Y-Labeled Anti-CD 22 Monoclonal Antibody (2005) (2)
The Use of Immunotoxins to Kill Neoplastic B Cells (1984) (2)
The use of cyclosporine , FK506 and SDZ NIM 811 to prevent CD25 quiescent peripheral blood mononuclear cells from producing HIV-1 (1996) (2)
Cloned neoplastic B cells release a growth factor which augments lymphokine-mediated proliferation of normal B cells. (1984) (2)
In vivo administration of Fab' fragments of anti-L3T4 (GK1.5) antibody inhibits the T helper cell function of murine lymph node cells. (1989) (2)
ANTILEUKEMIC EFFECTS OF ALLOGENEIC BONE MARROW ALLOGRAFTS IN MICE (1982) (2)
Effect of T cell-derived lymphokines containing B cell differentiation factor(s) for IgG (BCDF gamma) on gamma-specific mRNA in murine B cells. (1983) (2)
STRUCTURAL ANALYSIS OF THE I-A AND I-E/C ALLOANTIGENS (1979) (2)
A CD4-derived peptide carrier blocks acute HIV-1 infection in vitro and binds to gp120 in the presence of Walter-Reed stage 1-6 HIV+ sera. (1992) (2)
Selective Depletion of CD25+ Host-Reactive Donor Lymphocytes from Allografts Preserves a CD25− CD4+foxp3+ Fraction of T Cells and Thereby Provides a Source for Efficient Reconstitution of Regulatory T Cells and Additional GVHD Control. (2006) (2)
Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins. (1991) (2)
The Immunogenicity of Peptoid-Protein Conjugates (2016) (2)
MOLECULAR RELATIONSHIPS OF Ia ANTIGENS CONTROLLED BY THE SAME AND BY DIFFERENT SUBREGIONS OF THE I REGION (1976) (2)
Abnormally short serum half-lives of chimeric and human IgGs in NOD-SCID mice (P4184) (2013) (2)
Optimized clinical-scale culture conditions for ex vivoselective depletion of host-reactive donor lymphocytes: astrategy for GVHD prophylaxis in allogeneic peripheral bloodstem cell transplantation (2002) (2)
MOLECULAR MODIFICATIONS IN VSV-INFECTED CELLS (1979) (2)
OR.84. Separation of Individual Leukemia-Reactive from Alloreactive T-Cells and Selective Depletion of Alloreactivity in Allogeneic Hematopoietic Stem Cell Transplantation (2006) (1)
IMMUNOSUPPRESSION IN THE MURINE B CELL LEUKEMIA, BCL 1 : REQUIREMENT FOR A SUPPRESSOR MACROPHAGE AND A NORMAL T CELL (1982) (1)
IL-4 down-regulates the expression of J11d on murine B cells. (1991) (1)
PHASE I TRIAL OF ANTI-CD22 RICIN-A-CHAIN IMMUNOTOXIN (IgG-RFB4-dgA) FOR TREATMENT OF AIDS-LYMPHOMA: 90 (1997) (1)
B and T cell tumors : Proceedings of the Symposium on "B and T Cell Tumors: Biological and Clinical Aspects" held March 1-5, 1982, Squaw Valley, California (1982) (1)
Prophylactic intervention in RadLV-induced lymphomagenesis with an anti-IL-4 monoclonal antibody. (1997) (1)
Selective Depletion of Alloreacting CD25+ Cells from Stem Cell Allografts Can Reduce Acute Graft-Versus-Host Disease Following Matched Related Donor Transplantation. (2004) (1)
Regulation of the biological effects of IL-4 on murine T and B cells. (1989) (1)
The development of a novel anti-peptoid antibody for a peptoid-based vaccine platform (P4506) (2013) (1)
Pillars article: T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J. Exp. Med. 1982. 155: 734-748. (2013) (1)
A PHASE I STUDY EVALUATING THE USE OF ALLODEPLETED T CELLS TRANSDUCED WITH INDUCIBLE CASPASE 9 SUICIDE GENE AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (CASPALLO) (2009) (1)
Monoclonal anti tac antibody a suitable carrier for immunotoxin therapy in adult t cell leukemia (1984) (1)
Erratum: Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses (Blood (September 15, 2003) 102 (2292-2299)) (2004) (1)
Splenic B cells and antigen-specific B cells process anti-Ig in a similar manner. (1989) (1)
The effect of different enhancers on the ability of an anti-CD2S ricin a chain immunotoxin to deplete cells which are activated in an MLR (2000) (1)
Biochemical analysis of an MHC-linked hematopoietic cell surface antigen, Qa-2. (1981) (1)
Reconstitution of Regulatory T Cells after Selective Depletion of CD25+ Host-Reactive Donor Lymphocytes from Allografts and Association with Acute Graft-Versus-Host-Disease. (2005) (1)
The anti-CD19 immunotoxin (HD37-dgRTA) is more effective when combined with chemotherapy (2005) (1)
Metabolism of H-2 and Thy-1 (theta) alloantigens in murine thymocytes. (1974) (1)
A Humanized Monoclonal Antibody against the Enzymatic Subunit of Ricin Toxin Rescues Rhesus macaques from the Lethality of Aerosolized Ricin (2018) (1)
Immunotoxins: A New Approach to Cancer Therapy (2019) (1)
From the Department of Microbiology and the Immunology Graduate Program, University of Texas Health Science Center at Dallas, Dallas, Texas and the Institute for Immunology and Genetics, German Cancer (2003) (1)
Targeted Delivery of Carbon Nanotubes to Cancer Cells (2009) (0)
Activation of the gamma 1 gene by lipopolysaccharide and T cell-derived lymphokines containing a B cell differentiation factor for IgG1 (BCDF gamma). (1985) (0)
Receptor-Mediated Triggering and Tolerance in Murine B Cells (1979) (0)
OTYPES ON MEMORY B CELLS ABSORPTION OF THE ANTISERUM (2003) (0)
A phase I clinical trial of an anti-CD25-deglycosylated ricin a-chain immunotoxin (RFT5-SMPT-DGA) in patients with Hodgkin’s lymphoma restistent to conventional therapy (2007) (0)
Function of surface immunoglobulin on murine B cells. (1980) (0)
Selective depletion of alloreactive T cells and study of anti-tumor activity of specific T cell clones in patients with leukemia and renal carcinoma (2007) (0)
Dormancy Is Established Tumor After 1 Tumor Dormancy and Cell Signaling. V. Regrowth of the BCL (2014) (0)
Supplementary Data CR Oct 13 (2014) (0)
Beth Levine M.D. Prize in Autophagy Research. (2021) (0)
Combined targeting of exposed phosphatidylserine, CD47 and CD54 on human pancreatic tumor cells in a mouse xenograft model of human pancreatic cancer (P4455) (2013) (0)
THYMOCYTE SURFACE ANTIGEN TO THE gp 69 / 71 ENVELOPE GLYCOPROTEIN OF MURINE LEUKEMIA VIRUS (2003) (0)
PURE , ISAKSON , KAPPLER , MARRACK , KRAMMER , AND VITETTA 601 Materials and Methods Animals (2003) (0)
Selective depletion of alloreactive donor T cells by anti-CD25immunotoxin in allogeneic transplantation (2005) (0)
Anti-tumor characteristics of radiation-induced tumor-infiltrating neutrophils (2014) (0)
Variations in h-2 expression in p815 cells after infection with vesicular stomatitis virus. Abstr. (1979) (0)
CELL SURFACE IMMUNOGLOBULIN (1974) (0)
CELL SURFACE IMMUNOGLOBULIN (1974) (0)
Use of combinations of ricin A chain-containing immunotoxins to kill murine T lymphomas in vitro (1985) (0)
Effect of anti-nu antibodies on in vitro proliferation of adult and neonatal murine spleen cells and bcl1 tumor cells. Abstr. (1980) (0)
The appearance of alloreactive T cell clones correlates withclinical GVHD in patients undergoing allogeneic stem celltransplants (2002) (0)
Hematopoietic progenitor cell laboratory manual. Ex-vivoselective depletion of alloreactive donor T lymphocytes usingthe anti-CD25 immunotoxin RFT5-SMPT-dgA (2003) (0)
Biochemical demonstration- of anti-Qa activity in an H-2.28 public specificity antiserum (1978) (0)
The effects of anti-CD3 immunotoxin or ganciclovir on the development of human B cell tumors in SCID/PBL mice (1997) (0)
Univalent immunotoxins containing ricin A (IT-A) and richin B chains (IT-B) synergize in killing target cells in vitro (1985) (0)
Amino acid sequence studies on murine h-2 and ia antigens. Abstr. (1978) (0)
chemotherapeutic agent and an immunotoxin apoptosis in human B-lymphoma cells and synergize with a Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce (2013) (0)
Depletion of Regulatory T Cells Does Not Influence the Inflammatory Response Induced by High-dose Irradiation (2012) (0)
ASPECTS OF ALLOREACTIVTTY: LYMPHOKINE RELEASE FROM ALLOREACTIVE T CELL CLONES IN LONG-TERM CULTURE (1982) (0)
62 Selectively depleting host-reactive T cells from peripheral blood stem cell allografts — preliminary results of a feasibility study (2003) (0)
IMMUNOSUPPRESSION IN THE MURINE B CELL LEUKEMIA, BCL1: REQUIREMENT FOR A SUPPRESSOR MACROPHAGE AND A NORMAL T CELL11This work was supported by NIH grants AI-11851, AI-12789, CA-28149 and CA-23115. (1982) (0)
SYNTHESIS , SECRETION , AND CELL SURFACE EXPRESSION OF IMMUNOGLOBULIN IN MURINE THORACIC DUCT LYMPIIOCYTES (1974) (0)
Synergy between ricin-A and ricin-B containing immunotoxins (1984) (0)
Synthesis ofgerm-line ylimmunoglobulin heavy-chain transcripts inresting B cells: Induction byinterleukin 4andinhibition by interferon y (1989) (0)
or antileukemic responses Selective depletion of donor alloreactive T cells without loss of antiviral (2013) (0)
Structural analysis of the qa-2 alloantigen. Abstr. (1981) (0)
Humanized Monoclonal Antibody Rescues Rhesus macaques from Aerosolized Ricin Toxin Exposure (2018) (0)
Beth Levine M.D. Prize in Autophagy Research. (2021) (0)
Donor leukocyte infusions selectively depleted of alloreactiveT cells for allogeneic hematopoietic cell transplant recipients (2002) (0)
Structural Characterization of Murine Ia Alloantigens (1978) (0)
The Generation and Preclinical Evaluation of Multimeric Anti-Her-2 Antibodies (2000) (0)
Dormancy Is Established Tumor Dormancy and Cell Signaling. V. Regrowth of the BCL1 Tumor After (2013) (0)
The Use of Ricin a Chain-Containing Immunotoxins to Kill Neoplastic B Cells (1987) (0)
Pop - Suppl Data - Table 3 revised (2014) (0)
In vitro and in vivo inhibition of anti-gal secreting cells. (2000) (0)
ANTIGEN-DRIVEN ALTERATION IN SURFACE Ig ISOTYPES ON ANTIGEN BINDING CELLS (1979) (0)
The Journal of Molecular and Cellular Immunology Volume 4 , 1988-1990 (2011) (0)
Serum antibody profiling identifies vaccine-induced correlates of protection against aerosolized ricin toxin in rhesus macaques (2022) (0)
Characterization and anti-tumor activity of a chimeric tetravalent anti-CD22 monoclonal antibody (2007) (0)
IS there a clinical value for ricin a-chain immunotoxins in hodgkins lymphoma (2000) (0)
The expression of lyb-2.1 On murine b lymphocytes. Abstr. (1978) (0)
A novel platform to generate peptoid-based mimetic vaccines (P4504) (2013) (0)
Crosslinking snapshots of bacterial chemoreceptor squads (2006) (0)
The development of immunotoxins for the treatment of B-cell lymphoma (1993) (0)
Anticorps monoclonaux recombinants anti-cd19 (2010) (0)
The Generation and Preclinical Evaluation of Homodimeric Anti-Her-2 Antibodies (2001) (0)
LYMPHOID CELLS OF GERM-FREE MICE (2003) (0)
Methods for the detection, purification, and biochemical characterization of lymphoid cell surface antigens (1984) (0)
V. Release :from Murine Splenic Lymptiocytes* (2003) (0)
The Use of Cyclosporine , FKS 06 , and SDZ NIM 811 to Prevent CD 2 S-Quiescent Peripheral Blood Mononuclear Cells from Producing Human Immunodeficiency Virus (2010) (0)
Beth Levine M.D. Prize in Autophagy Research (2021) (0)
Histology and Histopathology ln vited Revie w Adhesion molecules as targets for cancer therapy (2010) (0)
Salt—Isoelectric—Density Gradient (SID) Purification of Rabbit IgG∗ (1969) (0)
SYNTHESIS, INTRACELLULAR D ISTRIBUTION, AND SECRETION OF IMMUNOGLOBULIN AND H-2 ANTIGEN I N (1973) (0)
Endosymbiosis: infection and cure. (1967) (0)
Structural studies on protein products of murine chromosome 17 : Partial amino acid sequence of an H-2 Kb molecule * ( histocompatibility antigens / radiolabeling / immunoprecipitation ) (0)
Synergy of Sequential and Concurrent Administration of a Deglycosylated Ricin A Chain-Containing Combined Anti-CD19 and Anti-CD22 Immunotoxin (Combotox) and Cytarabine in a Murine Model of Advanced Acute Lymphoblastic Leukemia (2011) (0)
Molecular modifications in vesicular stomatitis virus infected cells (1979) (0)
Deletion of neoplastic B cells by immunotoxins containing ricin A chains. (1984) (0)
Tumor dormancy in a murine B cell lymphoma (2017) (0)
Structural analyses of thymus-leukemia (tl) antigens in the mouse. Abbstr. (1981) (0)
The effect of immunizing female mice to f9 teratocarcinoma cells on subsequent conception. Abstr. (1978) (0)
Myeloma - specific T-cell clones can eliminate tumor cells andtheir long-term correlate with clinical outcomes in patientswith multiple myeloma (2009) (0)
Graft-versus-host disease prevention by selective depletion ofalloreactive donor T cells (2005) (0)
Dynamics of immunoglobulin and alloantigens on lymphocytes. (1974) (0)
Erratum: The roles of Fas and perforin in LAK T‐cell/bispecific antibody‐mediated killing of the murine B‐lymphoma cells, BCL1. Int. J. Cancer, 68, 822–827 (1996) (1997) (0)
Immunosuppression in the mouse b cell leukemia (bcl1). Abstr. (1981) (0)
Selective killing of malignant cells fey antibody-ricin conjugates (‘immunotoxins’) (1990) (0)
Hypersusceptibility to the lethal effects of bacterial lipopolysaccharide (lps) induced by a murine b cell leukemia (bcl1). Abstr. (1980) (0)
Normal in vitro splenic b cell tolerance susceptibility in adult auto- immune mice. Abstr. (1980) (0)
Pop - Suppl Data - Table 1 (2014) (0)
(RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (1997) (0)
immunotoxin cocktail an mice with disseminated Daudi lymphoma using chemotherapy and Eradication of minimal disease in severe combined immunodeficient (2011) (0)

This paper list is powered by the following services:

Other Resources About Ellen Vitetta

en.wikipedia.org

What Schools Are Affiliated With Ellen Vitetta?

Ellen Vitetta is affiliated with the following schools:

Ellen Vitetta's Academic­Influence.com Rankings